Aurobindo Pharma said the US FDA has completed its inspection at Eugia Pharma’s Unit-III formulation facility, issuing 11 procedural observations that the company will address within the stipulated timeframe.
Aurobindo Pharma says US FDA inspection at subsidiary ends with 11 procedural observations
